<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Clindamycin - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Clindamycin</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Clindamycin</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Clindamycin 300mg Capsules</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Skin and soft tissue infections (when appropriate pathogen coverage)</strong>
            <ul>
              <li>300 mg PO every 6 hours OR 450 mg PO every 8 hours</li>
              <li>Duration typically 5–10 days depending on severity/response</li>
            </ul>
          </li>
          <li><strong>MRSA skin infections (when MRSA suspected/confirmed and oral therapy appropriate)</strong>
            <ul>
              <li>300–450 mg PO every 6–8 hours for 7–14 days (based on severity)</li>
              <li>Confirm local susceptibility patterns (inducible clindamycin resistance exists)</li>
            </ul>
          </li>
          <li><strong>Dental infections / odontogenic infections</strong>
            <ul>
              <li>300 mg PO every 6 hours for 5–7 days</li>
            </ul>
          </li>
          <li><strong>Aspiration pneumonia (when anaerobic coverage needed and appropriate for severity)</strong>
            <ul>
              <li>300–450 mg PO every 6–8 hours for 7–14 days (or per clinical response)</li>
            </ul>
          </li>
          <li><strong>Streptococcal pharyngitis (penicillin allergy; alternative agent)</strong>
            <ul>
              <li>300 mg PO every 8 hours for 10 days</li>
            </ul>
          </li>
          <li><strong>Toxin-mediated streptococcal/staphylococcal infections (e.g., necrotizing fasciitis adjunct; toxic shock syndrome)</strong>
            <ul>
              <li>Used to reduce toxin production; typically combined with other antibiotics</li>
              <li>300–450 mg PO every 6–8 hours (or IV in severe cases; follow specialist guidance)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Skin and soft tissue infections (especially when MSSA/MRSA coverage needed; anaerobic coverage)</li>
          <li>Dental/odontogenic infections (good oral anaerobe coverage)</li>
          <li>Aspiration pneumonia (anaerobic pathogen coverage)</li>
          <li>Bone and joint infections (when appropriate organism and susceptibility)</li>
          <li>Streptococcal pharyngitis (penicillin-allergic patients; alternative)</li>
          <li>Toxin-mediated infections (adjunct to reduce toxin production in necrotizing fasciitis, toxic shock syndrome)</li>
          <li>Intra-abdominal infections (usually combined with other agents for gram-negative coverage)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to clindamycin or lincomycin</li>
          <li><strong>Black box warning:</strong> Clostridioides difficile-associated diarrhea (CDAD) and pseudomembranous colitis
            <ul>
              <li>Risk with nearly all antibiotics but historically notable with clindamycin</li>
              <li>Can occur during therapy or up to several months after discontinuation</li>
              <li>STOP drug if severe diarrhea develops; consider C. difficile testing and treatment</li>
            </ul>
          </li>
          <li>History of GI disease (especially inflammatory bowel disease or antibiotic-associated colitis)</li>
          <li>Hepatic impairment: use with caution; monitor liver function if prolonged use</li>
          <li>Caution in patients with history of atopy/allergies (higher hypersensitivity risk)</li>
          <li>Pregnancy/lactation: generally considered compatible when indicated; clindamycin crosses placenta and appears in breast milk</li>
          <li>Inducible clindamycin resistance: MRSA and some streptococci may have inducible resistance (D-test); confirm susceptibility when possible</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>GI upset (diarrhea, nausea, abdominal pain; very common)</li>
          <li>C. difficile-associated diarrhea / pseudomembranous colitis (important; black box warning)</li>
          <li>Hypersensitivity reactions (rash, urticaria; rarely severe reactions including Stevens-Johnson syndrome)</li>
          <li>Elevated liver enzymes</li>
          <li>Metallic or bitter taste</li>
          <li>Esophagitis (take with full glass of water; do not lie down immediately after)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>May take with or without food; taking with food may reduce GI upset</li>
          <li>Take capsule with full glass of water; remain upright for at least 30 minutes after dose to reduce esophagitis risk</li>
          <li>Take at evenly spaced intervals to maintain blood levels</li>
          <li>Counsel: finish prescribed course; report severe or persistent diarrhea immediately (C. difficile risk)</li>
          <li>If diarrhea develops: do NOT use antidiarrheal agents (e.g., loperamide) without medical guidance (may worsen C. difficile colitis)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response within 48–72 hours (symptoms, fever, local signs of infection)</li>
          <li>Diarrhea: monitor frequency and severity; STOP drug and evaluate for C. difficile if severe/bloody/persistent diarrhea develops</li>
          <li>Hypersensitivity reactions (rash, allergic symptoms)</li>
          <li>Liver function if prolonged course or baseline hepatic impairment</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Excellent MRSA coverage for skin/soft tissue infections when organism susceptible (confirm local resistance patterns when possible)</li>
          <li>Good anaerobic coverage: useful for dental infections, aspiration pneumonia, and polymicrobial infections</li>
          <li>C. difficile risk is significant: counsel patients clearly; monitor for diarrhea and stop drug if severe diarrhea develops</li>
          <li>If C. difficile colitis suspected: stop clindamycin, initiate supportive care, consider empiric C. difficile treatment if severe, and arrange evacuation if needed</li>
          <li>Ensure adequate hydration and avoid antidiarrheal agents if diarrhea develops</li>
          <li>Document indication, start date, planned duration, and allergy status clearly</li>
          <li>If infection not responding within 48–72 hours: reassess for resistant organism, alternate diagnosis, or need for escalation/evacuation</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (clindamycin capsules): <a href="https://pdf.hres.ca/dpd_pm/00068272.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00068272.PDF</a></li>
          <li>CDC - Clostridioides difficile information: <a href="https://www.cdc.gov/c-diff/index.html" target="_blank" rel="noopener">https://www.cdc.gov/c-diff/index.html</a></li>
          <li>Medscape - Clindamycin reference: <a href="https://reference.medscape.com/drug/cleocin-clindamycin-342561" target="_blank" rel="noopener">https://reference.medscape.com/drug/cleocin-clindamycin-342561</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
